Canakinumab in Patienten mit COVID-19 und Typ 2 Diabetes

Drug: Canakinumab;Drug: Placebo

Inclusion Criteria:

- Diagnosis of type 2 diabetes mellitus

- Body mass index > 25 kg/m² (overweight)

- Hospitalized with COVID-19

Exclusion Criteria:

- Suspected or known untreated active bacterial, fungal, viral, or parasitic infection
with the exception of COVID-19

- Treatment with immunomodulators or immunosuppressant drugs, including but not limited
to tocilizumab, tumor necrosis factor (TNF) inhibitors and anti-IL-17 agents within 5
half-lives or 30 days (whichever is longer) prior to randomization with the exception
of anakinra which is excluded within 5 half-lives only. Note: Immunomodulators
(topical or inhaled) for asthma and atopic dermatitis, and corticosteroids (any route
of administration) such as dexamethasone are permitted.

- History of hypersensitivity to canakinumab or to biologic drugs

- Neutrophil count <1000/mm3

- Pregnant or nursing (lactating) women

- Participation in another study with investigational drug within the 30 days preceding
and during the present study-